About Genentech in Influenza

Influenza, or flu, is one of the most common, yet serious, infectious diseases. Globally, annual epidemics result in 3 to 5 million cases of severe disease, millions of hospitalizations and up to 650,000 deaths worldwide. Although vaccines are an important first line of defense in preventing the flu, there is a need for further medical options for prophylaxis and treatment. 

Current antivirals have limitations as flu viruses, or “strains”, are constantly changing, so new antiviral medicines are necessary. Genentech, a Member of the Roche Group, is committed to addressing the unmet need in influenza.   

About Genentech 

For more than 40 years, we've been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, California.

Visit the website here

Bronze Sponsors

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it.

From viral hepatitis and human immunodeficiency virus (HIV) to respiratory syncytial virus (RSV) and influenza, the teams of people working in Infectious Diseases & Vaccines at Janssen have one mission. They work every day with the goal to discover and develop novel therapeutics and vaccines to prevent, treat and cure infectious diseases worldwide.

Learn more at https://www.janssen.com/infectious-diseases-and-vaccines and follow us at @JanssenGlobal

Seqirus is part of CSL Limited (ASX:CSL), headquartered in Melbourne, Australia. The CSL Group of companies employs more than 22,000 people with operations in more than 35 countries. Seqirus was established in 2015 following CSL’s acquisition of the Novartis influenza vaccines business and its subsequent integration with bioCSL. As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to influenza prevention and a transcontinental partner in pandemic preparedness and response.

Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies, as well as a proprietary adjuvant. It has leading R&D capabilities, a broad portfolio of differentiated products and a commercial presence in more than 20 countries. For more information visit www.seqirus.com